Stem Cell Therapy for Pulmonary Arterial Hypertension: An Update

Overview

Journal J Heart Lung Transplant

Publisher Elsevier

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2022 Mar 28

PMID 35341679

Authors

Qiwei Wilton Sun

Zhongjie Sun

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) remains a deadly disease, and there currently is no cure for this life-threating medical problem. The average lifespan is about 5 to 7 years after diagnosis of PAH. Therefore, a conceptual breakthrough to develop new therapeutic strategies for PAH is urgently needed. Growing evidence shows that stem cells are emerging as a novel effective treatment, but the understanding of its underlying mechanisms is still limited. This review highlights the mechanisms through which stem cells successfully reverse pulmonary vascular endothelial dysfunction, pulmonary artery smooth muscle cell over-proliferation, and mitochondrial dysfunction in PAH patients and common rodent models used in PAH research. They can modulate common underlying pathways involved in PAH, including the nitric oxide synthase, mitochondrial regulators, microRNAs and STAT3-BMPR signaling. Genetic modifications further enhance the therapeutic effects of stem cells on PAH. Clinical trials showed promising therapeutic potential of mesenchymal stem cells and endothelial progenitor cells for PAH. Potential limitations and challenges are also discussed. The current findings support the need for further investigation and validation of stem cell therapy for PAH.

Citing Articles

Stem cells in pulmonary hypertension: Current understanding and future challenges.

Hu X, Liu J, Song X, Yuan P Animal Model Exp Med. 2024; 7(6):961-963.

PMID: 39439226 PMC: 11680471. DOI: 10.1002/ame2.12482.

TNFα Induces DNA and Histone Hypomethylation and Pulmonary Artery Smooth Muscle Cell Proliferation Partly via Excessive Superoxide Formation.

Crosswhite P, Sun Z Antioxidants (Basel). 2024; 13(6).

PMID: 38929115 PMC: 11200563. DOI: 10.3390/antiox13060677.

Unlocking the Future: Pluripotent Stem Cell-Based Lung Repair.

Goecke T, Ius F, Ruhparwar A, Martin U Cells. 2024; 13(7.

PMID: 38607074 PMC: 11012168. DOI: 10.3390/cells13070635.

Low-frequency ultrasound for pulmonary hypertension therapy.

Ostasevicius V, Jurenas V, Venslauskas M, Kizauskiene L, Zigmantaite V, Stankevicius E Respir Res. 2024; 25(1):70.

PMID: 38317182 PMC: 10840147. DOI: 10.1186/s12931-024-02713-5.

Angiotensin-converting enzyme - human amniotic mesenchymal stem cells improve pulmonary vascular remodeling in rats with pulmonary hypertension by promoting angiogenesis and counteracting inflammation.

Wu C, Liu H, Ba M, Zha J, Gao Z, Li L Int J Clin Exp Pathol. 2023; 16(10):282-293.

PMID: 37970332 PMC: 10641367.

References

Crosswhite P, Sun Z . Molecular mechanisms of pulmonary arterial remodeling. Mol Med. 2014; 20:191-201. PMC: 4002851. DOI: 10.2119/molmed.2013.00165. View

Umar S, de Visser Y, Steendijk P, Schutte C, Laghmani E, Wagenaar G . Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009; 297(5):H1606-16. DOI: 10.1152/ajpheart.00590.2009. View

Archer S, Weir E, Wilkins M . Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010; 121(18):2045-66. PMC: 2869481. DOI: 10.1161/CIRCULATIONAHA.108.847707. View

Pena-Blanco A, Haschka M, Jenner A, Zuleger T, Proikas-Cezanne T, Villunger A . Drp1 modulates mitochondrial stress responses to mitotic arrest. Cell Death Differ. 2020; 27(9):2620-2634. PMC: 7429963. DOI: 10.1038/s41418-020-0527-y. View

Yang D, Huang W, Chen G, Chen S, Yang J, He R . Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism. Comput Biol Chem. 2020; 89:107383. DOI: 10.1016/j.compbiolchem.2020.107383. View

Smith K, Voiriot G, Tang H, Fraidenburg D, Song S, Yamamura H . Notch Activation of Ca(2+) Signaling in the Development of Hypoxic Pulmonary Vasoconstriction and Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2015; 53(3):355-67. PMC: 4566064. DOI: 10.1165/rcmb.2014-0235OC. View

Varshney R, Ali Q, Wu C, Sun Z . Monocrotaline-Induced Pulmonary Hypertension Involves Downregulation of Antiaging Protein Klotho and eNOS Activity. Hypertension. 2016; 68(5):1255-1263. PMC: 5063703. DOI: 10.1161/HYPERTENSIONAHA.116.08184. View

Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R . Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc. 2013; 2(1):e005157. PMC: 3603259. DOI: 10.1161/JAHA.112.005157. View

Hu H, Wang B, Jiang C, Li R, Zhao J . Endothelial progenitor cell-derived exosomes facilitate vascular endothelial cell repair through shuttling miR-21-5p to modulate Thrombospondin-1 expression. Clin Sci (Lond). 2019; 133(14):1629-1644. DOI: 10.1042/CS20190188. View

10.

Wang Y, Lam K, Xu J, Lu G, Xu L, Cooper G . Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005; 280(18):18341-7. DOI: 10.1074/jbc.M501149200. View

11.

Barst R . Is it possible to reverse the endothelial dysfunction in pulmonary arterial hypertension?. J Am Coll Cardiol. 2007; 49(14):1572-4. DOI: 10.1016/j.jacc.2007.01.054. View

12.

Crosswhite P, Sun Z . Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension. Hypertension. 2010; 55(6):1484-91. PMC: 2894564. DOI: 10.1161/HYPERTENSIONAHA.109.146902. View

13.

Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S . Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018; 198(1):90-103. PMC: 6835039. DOI: 10.1164/rccm.201708-1751OC. View

14.

Feng R, Ullah M, Chen K, Ali Q, Lin Y, Sun Z . Stem cell-derived extracellular vesicles mitigate ageing-associated arterial stiffness and hypertension. J Extracell Vesicles. 2020; 9(1):1783869. PMC: 7480600. DOI: 10.1080/20013078.2020.1783869. View

15.

Lavoie A, Hall J, Olson D, Wylam M . Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med. 1996; 153(6 Pt 1):1985-7. DOI: 10.1164/ajrccm.153.6.8665066. View

16.

Zhu Z, Fang Z, Hu X, Zhou S . MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension. Rev Bras Cir Cardiovasc. 2015; 30(3):380-5. PMC: 4541786. DOI: 10.5935/1678-9741.20150033. View

17.

Han X, Zhang W, Wang Q, Li M, Zhang C, Yang Z . HIF-1α promotes the proliferation and migration of pulmonary arterial smooth muscle cells via activation of Cx43. J Cell Mol Med. 2021; 25(22):10663-10673. PMC: 8581339. DOI: 10.1111/jcmm.17003. View

18.

You D, Waeckel L, Ebrahimian T, Blanc-Brude O, Foubert P, Barateau V . Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy. Circulation. 2006; 114(4):328-38. DOI: 10.1161/CIRCULATIONAHA.105.589937. View

19.

Marsboom G, Toth P, Ryan J, Hong Z, Wu X, Fang Y . Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012; 110(11):1484-97. PMC: 3539779. DOI: 10.1161/CIRCRESAHA.111.263848. View

20.

Dewachter L, Dewachter C, Naeije R . New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs. 2010; 19(4):469-88. DOI: 10.1517/13543781003727099. View